logo

Clinical Trial Calendar

Clinical trials are binary speculative events that could make or break biotech stocks. Therefore, knowing the timing of announcement of results for phase I, phase II and phase III clinical studies helps limit risk and maximize profits when trading/investing in biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending clinical trial catalysts. The column "Results Date" refers to the announcement timing of the clinical trial results. But not every time is the schedules and deadlines followed by the companies, because sometimes the results may be announced early if the trial is stopped early due to efficacy or there may be a delay in reporting the results if there are unexpected hurdles in completing the clinical study.
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
1H 2015
CytRx Corp.
Preliminary results from phase II trial of Aldoxorubicin
Kaposi's Sarcoma
1H 2015
CytRx Corp.
Preliminary results from phase II trial of Aldoxorubicin
Glioblastoma multiforme
1H 2015
Can-Fite BioPharma Ltd.
Data from Phase II study of CF101
Glaucoma.
1H 2015
Immunomedics Inc.
Phase 3 data of Epratuzumab
Systemic lupus
Q2 2015
Biomarin Pharmaceutical Inc.
Data from phase 2 study of BMN 111
Achondroplasia
Q2 2015
Apricus Biosciences, Inc.
Results from phase 2a trial of RayVa
Raynaud's phenomenon, a circulatory disorder affecting the hands and feet.
Late Q2 2015
Genocea Biosciences, Inc.
Topline data from Phase 2 trial of GEN-003
Genital herpes
Q2 2015
GTX Inc.
Topline data from Phase 2 study of GTx-758
Metastatic and non-metastatic castration resistant prostate cancer
Q2 2015
Eleven Biotherapeutics, Inc.
Top-line results from phase 3 study of EBI-005
Dry eye disease
Q2 2015
Conatus Pharmaceuticals Inc
Initial baseline data from phase 2 study of Emricasan
Post Orthotopic Liver Transplant for Chronic HCV patients
Q2 2015
Otonomy Inc.
Results from Phase 2b trial of OTO-104
Meniere's disease
Q2 2015
Ardelyx, Inc
Phase 2a Data for Tenapanor
Chronic kidney disease
Mid 2015
Alnylam Pharmaceuticals Inc.
Data from Phase 2 study of Patisiran
Familial amyloidotic polyneuropathy (FAP)
Mid 2015
Avalanche Biotechnologies, Inc.
1 year follow-up results from Phase 2a trial of AVA-101
wet AMD
Mid 2015
Aquinox Pharmaceuticals, Inc.
Top-line results from Phase 2 trial of AQX-1125
Bladder pain syndrome/interstitial cystitis in females
Mid 2015
Aquinox Pharmaceuticals, Inc.
Top-line results from Phase 2 trial of AQX-1125
Chronic obstructive pulmonary disease exacerbations
Mid 2015
Recro Pharma Inc.
Top-line data from Phase II trial of Dex-IN
Pain following bunionectomy surgery
Mid 2015
Vical Inc.
Efficacy data from phase 1/2 trial of Vaxfectin(R)-formulated therapeutic vaccine
Herpes simplex virus type 2 (HSV-2)
Mid 2015
Trevena, Inc.
Data from Phase 2b Study of TRV130
Acute Postoperative Pain
Mid 2015
Fate Therapeutics, Inc
Full data on primary efficacy endpoint from phase II study of PROHEMA
Hematologic malignancies
Mid 2015
Celldex Therapeutics Inc.
First interim analysis of phase III 3 Study of Rindopepimut
Frontline Glioblastoma
Mid 2015
Fate Therapeutics, Inc
Full data on primary efficacy endpoint from phase II study of PROHEMA
Hematologic malignancies in adult subjects undergoing double umbilical cord blood transplantation
Mid 2015
Esperion Therapeutics
Top-line results from phase 2 study of ETC-1002
Hypercholesterolemia and hypertension
Mid 2015
Galena Biopharma, Inc.
Top line data from Phase 2a trial of GALE-301
Ovarian and endometrial cancers
Jun 2015
RedHill Biopharma Ltd.
Top-line data from the first Phase 3 trial of RHB-105
For the treatment of H. pylori bacterial infection